News

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the

Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for

The Humana Foundation, the philanthropic arm of Humana Inc. for the past 44 years, today announced the publication of its new report, Strengthening Science and Community Impact Through Equitable

Acadia Healthcare (NASDAQ: ACHC) (“Acadia” or the “Company”) today announced that it will release its first quarter 2025 financial results on Monday, May 12, 2025, after the close of the market

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2025 financial results on Wednesday, May 7^th, before the market opens. A conference call has been scheduled to

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to seven new employees.

On April 9

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance

Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2025 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 24

Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2025 third quarter on Tuesday, May 6, 2025, at approximately 6:30 a.m. ET. The company will also

Natus Sensory freut sich, die Erweiterung seines globalen Führungsteams um drei erfahrene Führungskräfte bekannt zu geben. Damit bekräftigt das Unternehmen sein Engagement für die Förderung von

Natus Sensory is pleased to announce the addition of three accomplished executives to its global leadership team, reinforcing the company’s commitment to advancing innovation, customer impact, and